Matches in SemOpenAlex for { <https://semopenalex.org/work/W2590410823> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- W2590410823 endingPage "e14506" @default.
- W2590410823 startingPage "e14506" @default.
- W2590410823 abstract "e14506 Background: Stereotactic body radiation therapy (SBRT) offers a non-invasive, and short-in-duration option for patients with advanced pancreatic adenocarinoma for palliation or local control. Methods: Gold fiducial seed markers (1-4) were placed in, or around, the tumor in the pancreas to guide tracking of the tumor. Triple phase contrast CT images, and as necessary PET/CT, or MRI images were obtained for treatment planning. Treatment planning was performed using the MultiPlan treatment planning (Accuray Incorporated, Sunnyvale, CA). Treatment was performed using the CyberKnife with Synchrony motion tracking. A 3-5 mm margin was added to gross disease to specify the planning target volume (PTV). Results: Between July 2007 and January 2010, 26 pancreatic cancer patients were treated for 27 tumors with SBRT at CyberKnife Centers of San Diego. 12 patients were locally advanced, 12 patients had metastatic disease, 1 patient had recurrence following surgery, and 1 patient refused surgery. 9 patients had prior external radiation therapy (45-50.4 Gy) with concurrent chemotherapy. Twelve patients had received prior chemotherapy alone. The median lesion volume was 46.7 cc (10.1-263.8 cc). Typical prescribed doses was 35 Gy in 5 fractions. All patients tolerated treatments well with no grade 3 or 4 toxicities. Five grade 2 acute toxicities and two grade 2 late toxicities were observed. Fourteen of the patients presented with pain; of these 12 (86%) had substantial pain relief from SBRT, 1 (7%) minor and 1 (7%) had no pain relief. For the 18 patients with a minimum of 3 months follow-up (3-24 months), 14 (78%) were locally controlled, 3 had local failures and 1 had unknown local control. Median overall survival from time of diagnosis was 10.9 months (range, 3-31 months). The median overall survival length from time of SBRT was 5.4 months (range, 1-24 months). Kaplan-Meier estimated overall survival from time of diagnosis was 96%, 88%, 42% and 12% at 3, 6, 12 and 24 months, respectively. Conclusions: In this group of heavily pre-treated patients with advanced pancreatic cancer, CyberKnife SBRT was well tolerated and offered a quick palliation with good local control." @default.
- W2590410823 created "2017-03-03" @default.
- W2590410823 creator A5026731460 @default.
- W2590410823 creator A5055191335 @default.
- W2590410823 creator A5077198313 @default.
- W2590410823 creator A5088073833 @default.
- W2590410823 date "2011-05-20" @default.
- W2590410823 modified "2023-10-18" @default.
- W2590410823 title "CyberKnife stereotactic body radiation therapy for palliation and local control in patients with advanced pancreatic cancer: A retrospective review." @default.
- W2590410823 doi "https://doi.org/10.1200/jco.2011.29.15_suppl.e14506" @default.
- W2590410823 hasPublicationYear "2011" @default.
- W2590410823 type Work @default.
- W2590410823 sameAs 2590410823 @default.
- W2590410823 citedByCount "1" @default.
- W2590410823 crossrefType "journal-article" @default.
- W2590410823 hasAuthorship W2590410823A5026731460 @default.
- W2590410823 hasAuthorship W2590410823A5055191335 @default.
- W2590410823 hasAuthorship W2590410823A5077198313 @default.
- W2590410823 hasAuthorship W2590410823A5088073833 @default.
- W2590410823 hasConcept C121608353 @default.
- W2590410823 hasConcept C126322002 @default.
- W2590410823 hasConcept C126838900 @default.
- W2590410823 hasConcept C141071460 @default.
- W2590410823 hasConcept C167135981 @default.
- W2590410823 hasConcept C201645570 @default.
- W2590410823 hasConcept C2776651944 @default.
- W2590410823 hasConcept C2780210213 @default.
- W2590410823 hasConcept C2780387249 @default.
- W2590410823 hasConcept C2989005 @default.
- W2590410823 hasConcept C509974204 @default.
- W2590410823 hasConcept C71924100 @default.
- W2590410823 hasConceptScore W2590410823C121608353 @default.
- W2590410823 hasConceptScore W2590410823C126322002 @default.
- W2590410823 hasConceptScore W2590410823C126838900 @default.
- W2590410823 hasConceptScore W2590410823C141071460 @default.
- W2590410823 hasConceptScore W2590410823C167135981 @default.
- W2590410823 hasConceptScore W2590410823C201645570 @default.
- W2590410823 hasConceptScore W2590410823C2776651944 @default.
- W2590410823 hasConceptScore W2590410823C2780210213 @default.
- W2590410823 hasConceptScore W2590410823C2780387249 @default.
- W2590410823 hasConceptScore W2590410823C2989005 @default.
- W2590410823 hasConceptScore W2590410823C509974204 @default.
- W2590410823 hasConceptScore W2590410823C71924100 @default.
- W2590410823 hasIssue "15_suppl" @default.
- W2590410823 hasLocation W25904108231 @default.
- W2590410823 hasOpenAccess W2590410823 @default.
- W2590410823 hasPrimaryLocation W25904108231 @default.
- W2590410823 hasRelatedWork W1998385533 @default.
- W2590410823 hasRelatedWork W2032769033 @default.
- W2590410823 hasRelatedWork W2053511483 @default.
- W2590410823 hasRelatedWork W2063122912 @default.
- W2590410823 hasRelatedWork W2897436171 @default.
- W2590410823 hasRelatedWork W2939840252 @default.
- W2590410823 hasRelatedWork W2953263120 @default.
- W2590410823 hasRelatedWork W3029654687 @default.
- W2590410823 hasRelatedWork W4236693431 @default.
- W2590410823 hasRelatedWork W2346725849 @default.
- W2590410823 hasVolume "29" @default.
- W2590410823 isParatext "false" @default.
- W2590410823 isRetracted "false" @default.
- W2590410823 magId "2590410823" @default.
- W2590410823 workType "article" @default.